Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

XML

Research Article

Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy

Online download statistics by month:

Online download statistics by month: December 2019 to May 2022

	Abstract	Full	Pdf
Dec 2019	1	1	0
Jan 2020	5	5	2
Feb 2020	16	16	5
Mar 2020	22	22	7
Apr 2020	32	32	8
May 2020	41	41	3
Jun 2020	32	32	4
Jul 2020	25	25	8
Aug 2020	24	24	3
Sep 2020	59	59	9
Oct 2020	74	74	13
Nov 2020	51	51	10
Dec 2020	41	41	6
Jan 2021	37	37	8
Feb 2021	36	36	8
Mar 2021	49	49	10
Apr 2021	43	43	17
May 2021	37	37	13
Jun 2021	114	114	15
Jul 2021	29	29	10
Aug 2021	40	40	9
Sep 2021	48	48	8
Oct 2021	74	74	20
Nov 2021	58	58	21
Dec 2021	39	39	7
Jan 2022	55	60	14
Feb 2022	44	46	9
Mar 2022	74	79	23
Apr 2022	96	106	24
May 2022	99	102	12
Total	1395	1420	306